Oncology Institute (NASDAQ:STLN) Earns Buy Rating from B. Riley Financial

Oncology Institute (NASDAQ:STLN)‘s stock had its “buy” rating reaffirmed by analysts at B. Riley Financial in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $10.00 price objective on the stock, down from their prior price objective of $11.00. B. Riley Financial‘s price target suggests a potential upside of 121.68% from the company’s current price.

A number of other equities research analysts have also recently issued reports on STLN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research report on Tuesday. BTIG Research increased their price target on Oncology Institute from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday. Finally, Needham & Company LLC lifted their price target on shares of Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.75.

Oncology Institute Stock Down 32.7%

Shares of NASDAQ:STLN traded down $2.19 on Friday, reaching $4.51. The company had a trading volume of 4,781,300 shares, compared to its average volume of 1,746,772. The stock has a market cap of $445.87 million, a PE ratio of -15.03 and a beta of 0.44. The company has a 50-day moving average of $6.49. Oncology Institute has a twelve month low of $2.32 and a twelve month high of $7.13.

Oncology Institute (NASDAQ:STLN) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $169.77 million during the quarter. On average, research analysts anticipate that Oncology Institute will post -0.21 EPS for the current year.

Insider Buying and Selling at Oncology Institute

In related news, Director Brad Hively sold 298,853 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the completion of the transaction, the director directly owned 411,976 shares in the company, valued at $2,681,963.76. This represents a 42.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 12,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $6.54 per share, with a total value of $78,480.00. Following the completion of the purchase, the insider owned 10,660,858 shares in the company, valued at approximately $69,722,011.32. The trade was a 0.11% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in STLN. Bank of New York Mellon Corp acquired a new stake in shares of Oncology Institute during the 2nd quarter valued at about $961,000. Bank of America Corp DE acquired a new stake in shares of Oncology Institute during the 2nd quarter valued at about $2,129,000. State Street Corp bought a new stake in Oncology Institute in the second quarter valued at about $8,432,000. Arrowstreet Capital Limited Partnership increased its stake in Oncology Institute by 169.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 419,423 shares of the company’s stock valued at $1,288,000 after acquiring an additional 263,699 shares during the period. Finally, Cetera Investment Advisers raised its position in Oncology Institute by 427.8% in the first quarter. Cetera Investment Advisers now owns 128,195 shares of the company’s stock worth $394,000 after purchasing an additional 103,908 shares in the last quarter. Institutional investors own 36.86% of the company’s stock.

Key Oncology Institute News

Here are the key news stories impacting Oncology Institute this week:

• Positive Sentiment: BTIG Research raised its price target to $10 from $9 and reiterated a Buy rating. The new target implies substantial upside from the price cited in the report. Tickerreport article
• Positive Sentiment: Third-quarter revenue beat estimates, and the per-share loss narrowed to $0.13 from $0.14 a year earlier. Zacks earnings article
• Negative Sentiment: The company reported a third-quarter loss of $0.13 per share, worse than the $0.07 loss analysts expected. The earnings shortfall is a near-term negative, despite the year-over-year improvement. Third-quarter results and guidance

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.